leukemia-screening-market

Diagnostics Segment is the largest segment driving the growth of Leukemia Screening Market

by

The global Leukemia Screening Market is estimated to be valued at US$ 17.04 Bn or Mn in 2023 and is expected to exhibit a CAGR of 6.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Leukemia screening involves various diagnostic tests such as complete blood count, blood smear, bone marrow aspiration and biopsy, cytogenetic tests and molecular genetic tests. These tests help in early and accurate diagnosis of leukemic conditions.

 

Market key trends:

The major key trend in the leukemia screening market involves development and commercialization of advanced genomic screening techniques. For instance, companies such as ArcherDx, Illumina and BioRad are developing next-generation sequencing (NGS) panels for genetic screening of leukemia. NGS allows comprehensive screening of multiple genes simultaneously, thereby enabling early detection and guiding treatment decisions. Furthermore, companies such as Adaptive Biotechnologies are developing sequencing techniques using T-cell receptors for detecting minimal residual disease in leukemia patients, improving monitoring and care.

The leukemia screening market has been witnessing growing adoption of new approaches and trends such as polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH), and next-generation sequencing (NGS). PCR and FISH techniques are highly commonly used for leukemia diagnosis and screening. However, NGS is a newer and promising technique due to advantages such as high accuracy, sensitivity, and ability to test multiple genes simultaneously. NGS allows screening of multiple genes and identification of genetic variations associated with leukemia.

SWOT Analysis

Strengths: Advanced tools such as PCR, FISH, and NGS allow quick, accurate, and easy diagnosis of various leukemia types.
Weaknesses: High costs associated with latest tools such as NGS limits their widespread adoption. Requirement of skilled personnel.
Opportunities: Rising leukemia incidence rates globally presents growth opportunities. Growth prospects in developing regions.
Threats: Presence of alternative cancer screening techniques. Stringent regulations for new product approval.

Key Takeaways

The global leukemia screening market size was valued at US$ 17.04 Bn in 2023 and is expected to reach US$ 28.63 Bn by 2030, expanding at a CAGR of 6.4% during the forecast period. The market is primarily driven by increasing prevalence of leukemia globally.

Regional analysis: North America dominated the global market in 2023 and is expected to continue its dominance over the forecast period. This is attributed to presence of advanced healthcare infrastructure, high adoption of advanced screening tools, and growing number of leukemia cases in the US and Canada.

Key players: Key players operating in the leukemia screening market are F. Hoffmann-La Roche Ltd, Abbott Laboratories, Thermo Fisher Scientific Inc., Sysmex Corporation, Bio-Rad Laboratories, Inc., Illumina, Inc., QIAGEN N.V., Grifols, S.A., Siemens Healthineers AG, Agilent Technologies, Inc., Ortho Clinical Diagnostics, Biocept, Inc., Adaptive Biotechnologies Corporation, Invivoscribe, Inc., and ArcherDX, Inc.